Libido Boost Pen

The Libido Pen

Understanding PT141:
This product is a reusable pen system, which uses refill cartridges for precise and convenient delivery.

Product Strength: 10mg per 3ml cartridge

Storage: Keep at room temperature between 20–25 °C to maintain potency and stability.

What It Is

PT-141 (bremelanotide) is a synthetic heptapeptide and a melanocortin receptor (MCR) agonist. It is a cyclic peptide analog derived from alpha-melanocyte-stimulating hormone (α-MSH), which was originally developed as a derivative of the research compound Melanotan II.

The discovery of PT-141's effects on sexual function came from an unexpected observation during early tanning research: a researcher who inadvertently took a high dose of Melanotan II experienced a prolonged erection, leading to the development of PT-141 as a targeted treatment for sexual dysfunction. In June 2019, the U.S. Food and Drug Administration (FDA) approved bremelanotide under the brand name Vyleesi® for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.

Mechanism of Action

PT-141 functions as a non-selective agonist at melanocortin receptors, with its primary clinical activity attributed to activation of the MC3R and MC4R subtypes in the central nervous system. Unlike traditional treatments for erectile dysfunction (such as PDE5 inhibitors like Viagra) that work by increasing blood flow to the genitals, PT-141 acts centrally in the brain to influence sexual desire and arousal at the neurological level.

By activating MC4 receptors in the hypothalamus, particularly in the medial preoptic area (MPOA), PT-141 triggers a cascade of neurochemical events that increase dopamine release in brain regions responsible for sexual motivation and reward processing, including the nucleus accumbens and ventral tegmental area. This central action enables PT-141 to enhance sexual desire independently of sexual stimulation, addressing both the mental and physical components of sexual function.

Key Research Applications & Uses

FDA-Approved Indication:

• Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women: PT-141 is approved for the treatment of acquired, generalized HSDD characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, relationship problems, or the effects of medication or drug substance

Off-Label & Research Uses:

• Erectile Dysfunction (ED) in men: PT-141 is used off-label to treat erectile dysfunction, particularly in men who do not respond adequately to conventional PDE5 inhibitors. A double-blind, placebo-controlled study found that approximately 80% of men developed an erection satisfactory for intercourse after using PT-141

• Low libido in men: The peptide is also used to enhance sexual desire and motivation in men experiencing low libido, regardless of the underlying cause

• Female Sexual Arousal Disorder (FSAD): Beyond HSDD, research has explored PT-141's potential benefits for general female sexual arousal disorders

• Combination therapy: Emerging evidence suggests PT-141 may provide synergistic effects when used alongside PDE5 inhibitors (e.g., sildenafil, tadalafil) for patients with partial responses to either treatment alone

Administration & Dosage

PT-141 is typically administered via subcutaneous injection, though compounded intranasal formulations are also available.

Timing: Administer at least 45 minutes (range: 30 minutes to 1 hour) before anticipated sexual activity

Frequency: Do not use more than one dose within 24 hours. The safety of using more than 8 doses per month has not been established

Onset & Duration:

Onset: Effects typically begin within 30–60 minutes

Duration: Effects can last between 6 to 12 hours, with some users reporting residual effects for up to 24 hours

Contraindications & Precautions

PT-141 is contraindicated in individuals with the following conditions:

Uncontrolled hypertension or cardiovascular disease: PT-141 causes a transient increase in blood pressure and a decrease in heart rate after administration. It should not be used in individuals with uncontrolled high blood pressure or known cardiovascular disease

Pregnancy: PT-141 is contraindicated during pregnancy. Women of reproductive potential should use effective contraception

Hypersensitivity: Known allergy to bremelanotide or any component of the formulation

Severe renal or hepatic impairment: Use with caution as drug exposure may be increased

Concurrent use with naltrexone: PT-141 may reduce the levels and effectiveness of naltrexone. Avoid using these drugs together

Adverse Reactions & Side Effects

The most common side effects associated with PT-141 are generally mild to moderate and include:

Nausea: The most frequent side effect, occurring in up to 40% of users. It may last for more than two hours but often improves with subsequent doses

Flushing: A feeling of warmth and redness of the skin, occurring in 20–21% of users

Headache: Mild to moderate, occurring in 11–12% of users

Injection site reactions: Redness, pain, or irritation at the injection site

Vomiting: Less common

Dizziness: Less common

Stuffy nose

Tiredness or fatigue

Tingling sensation in fingers and toes

Increased heart rate

Nervousness

Long-Term or Rare Side Effects:

Hyperpigmentation: Darkening of the skin on the face, gums, or breasts, particularly with frequent use (more than 8 doses per month). This change may not be fully reversible after discontinuation

Transient increases in blood pressure: Temporary but clinically significant increases in blood pressure have been observed

Disclaimer:

This information is for general knowledge and educational purposes only and does not constitute medical advice.  Always consult with a qualified medical professional regarding any cosmetic or medical procedure.